Lung Cancer: Overview, Diagnosis, and Treatment

Lung cancer is a serious disease with significant health implications worldwide. Understanding its types, how it's diagnosed, and the available treatment options is crucial for medical students and healthcare professionals alike. This article provides a comprehensive overview of lung cancer, its diagnosis, and treatment, drawing from essential study materials.

Understanding Lung Cancer: Types and Risk Factors

Lung cancer is broadly categorized into two main types, which dictate the approach to treatment. It's essential to differentiate between these types for effective patient management.

Pathologic Types of Lung Cancer

There are two primary subgroups:

• Small Cell Lung Cancer (SCLC): Accounts for about 25% of all lung cancers. These tumors tend to narrow bronchi by easy compression and often lead to widespread metastases, with 50%–75% of patients having metastases outside the chest at diagnosis.
• Nonsmall Cell Lung Cancer (NSCLC): Represents approximately 75% of lung cancers. This group includes squamous cell carcinoma (30%), adenocarcinoma (35% – most common type, often peripheral), and large cell carcinoma (5%–10% – usually peripheral).

Key Risk Factors for Lung Cancer

Several factors significantly increase the risk of developing lung cancer, with cigarette smoking being the most prominent:

• Cigarette Smoking: Accounts for over 85% of cases, showing a linear relationship between pack-years and risk. Adenocarcinoma has the lowest association with smoking among all lung cancers.
• Second-hand Smoke: Exposure to others' smoke also increases risk.
• Asbestos: Common in industries like shipbuilding and construction. The combination of smoking and asbestos synergistically increases risk.
• Radon: High levels can be found in basements.
• COPD: An independent risk factor, even after accounting for smoking history.

Clinical Features and Symptoms of Lung Cancer

Unfortunately, lung cancer is often asymptomatic in its early stages. When symptoms do appear, they are usually nonspecific, and the disease may already be widespread. By the time symptoms are present, the patient often requires prompt treatment.

Local Manifestations

These symptoms often arise from the tumor's growth or its effect on nearby structures (squamous cell carcinoma is frequently associated with these):

• Airway Involvement: Can cause persistent cough (sometimes with hemoptysis), obstruction, wheezing, and dyspnea.
• Recurrent Pneumonia: Often a sign of postobstructive pneumonia.

Constitutional Symptoms

These are general body symptoms, usually indicating advanced disease:

• Anorexia (loss of appetite)
• Weight loss
• Weakness

Local Invasion and Compression of Nerves

Tumor invasion into adjacent structures can lead to specific syndromes:

• Superior Vena Cava (SVC) Syndrome: Occurs in 5% of patients, commonly with SCLC. Caused by obstruction of the SVC, leading to facial fullness, facial and arm edema, dilated veins over the chest, arms, and face, and jugular venous distention (JVD).
• Phrenic Nerve Palsy: Affects 1% of patients, causing hemidiaphragmatic paralysis and dyspnea.
• Recurrent Laryngeal Nerve Palsy: Occurs in 3% of patients, leading to hoarseness.
• Horner Syndrome: Due to invasion of the cervical sympathetic chain by an apical tumor, characterized by unilateral facial anhidrosis (no sweating), ptosis (drooping eyelid), and miosis (constricted pupil).
• Pancoast Tumor (Superior Sulcus Tumor): An apical tumor involving C8 and T1–T2 nerve roots, causing shoulder pain radiating down the arm, upper extremity weakness, and often associated with Horner syndrome (60% of cases). Usually squamous cell carcinoma.

Paraneoplastic Syndromes

These are remote effects of the tumor, often due to substances secreted by cancer cells, and can be the first signs of lung cancer:

• SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion): Most commonly seen in SCLC (10% of SCLC patients).
• Ectopic ACTH Secretion: Associated with SCLC.
• PTH-like Hormone Secretion: Most common with squamous cell carcinoma.
• Hypertrophic Pulmonary Osteoarthropathy: Can cause severe long-bone pain, seen with adenocarcinoma and squamous carcinoma.
• Eaton–Lambert Syndrome: Most common in SCLC; presents with proximal muscle weakness, fatigability, diminished deep tendon reflexes, and paresthesias (especially in lower extremities).
• Digital Clubbing: Loss of the normal angle between the fingernail and nail bed due to subungual soft tissue thickening.

Diagnosing Lung Cancer: Key Steps and Tools

Tissue diagnosis is crucial to differentiate between SCLC and NSCLC, as treatment approaches vary significantly. The diagnostic process often begins with incidental findings and progresses to targeted imaging and biopsies.

Initial Findings and Solitary Pulmonary Nodule (SPN)

• Lung cancer is often discovered incidentally on a Chest X-ray (CXR) performed for another reason. CXR may show abnormal findings in nearly all patients with lung cancer and can reveal pleural effusion.
• A Solitary Pulmonary Nodule (SPN) is a single, well-circumscribed nodule without associated mediastinal or hilar lymph node involvement. The main question is whether it's malignant. Resection can lead to a cure with early detection.

Features Favoring Malignancy in SPNs

Diagnostic Imaging and Procedures

1. Chest CT Scan with IV Contrast: The test of choice. It's highly useful for staging, demonstrating the extent of local and distant metastasis, and accurately revealing mediastinal lymphadenopathy.
2. Cytologic Examination of Sputum: Can diagnose central tumors in about 80% of cases but is less effective for peripheral lesions. Results are variable.
3. Fiberoptic Bronchoscopy: Useful for diagnosing central, visualized tumors. The larger and more central the lesion, the higher the diagnostic yield.
4. Whole Body Positron Emission Tomography (PET): Provides additional information on tumor malignancy, and detects lymph node, intrathoracic, and distant metastases.
5. Transthoracic Needle Biopsy (under fluoroscopic or CT guidance): Highly accurate for suspicious pulmonary masses, especially peripheral lesions. It's an invasive procedure for selected patients.
6. Mediastinoscopy: Allows direct visualization of the superior mediastinum and helps identify patients with advanced disease who may not benefit from surgical resection.

Always perform a biopsy for intrathoracic lymphadenopathy, as pathologic confirmation is required for a definitive diagnosis of lung cancer.

Staging and Prognosis of Lung Cancer

Staging determines the extent of the cancer and guides treatment decisions. The prognosis for lung cancer is generally grim, highlighting the importance of early detection.

NSCLC Staging (TNM System)

NSCLC is staged using the well-established TNM (Tumor, Node, Metastasis) system, which assesses the size of the primary tumor, involvement of regional lymph nodes, and presence of distant metastasis.

SCLC Staging

SCLC is staged differently, though TNM staging is sometimes recommended:

• Limited Disease: Confined to the chest plus supraclavicular nodes, but not cervical or axillary nodes.
• Extensive Disease: Cancer has spread outside the chest and supraclavicular nodes.

Prognosis

• The overall 5-year survival for lung cancer patients is 14%.
• SCLC Prognosis:
• Limited Disease: 5-year survival is 10% to 13% (median survival 15 to 20 months).
• Extensive Disease: 5-year survival rate is 1% to 2% (median survival 8 to 13 months). Approximately 85% of SCLC patients have extensive disease at presentation, and most die within two years.
• Malignant Pleural Effusion: Occurs in 10% to 15% of patients. Indicates a very poor prognosis, equivalent to distant metastases.
• Metastatic Disease: Most common sites are the brain, bone, adrenal glands, and liver.

Treatment Approaches for Lung Cancer

Treatment strategies depend significantly on the type and stage of lung cancer. The primary goal is to provide the best possible outcome for the patient.

Treatment for NSCLC

• Surgery: Often the best option if the cancer is localized. A definitive pathologic diagnosis is required before surgery. Patients with metastatic disease outside the chest are generally not surgical candidates. Recurrence can occur even after complete resection.
• For high-probability malignant nodules, biopsy followed by lobectomy if appropriate is recommended.
• Radiation Therapy: An important adjunct to surgery, especially for local control.
• Chemotherapy: Of uncertain benefit, though some studies show a modest increase in survival. More trials are underway.

Treatment for SCLC

SCLC is typically treated with systemic therapies due to its aggressive nature and early metastasis:

• Limited Disease: Combination of chemotherapy and radiation therapy is used initially.
• Extensive Disease: Chemotherapy is used alone as initial treatment.
• Prophylactic Radiation: If the patient responds to initial chemotherapy, prophylactic radiation to the brain can decrease the incidence of brain metastases and prolong survival.
• Surgery: Has a limited role as SCLC tumors are usually nonresectable.

Frequently Asked Questions (FAQ) about Lung Cancer

What is the most common type of lung cancer?

Adenocarcinoma is the most common type of lung cancer, accounting for about 35% of all lung cancers, and it is often found in the periphery of the lungs.

Why is it crucial to differentiate between SCLC and NSCLC for treatment?

It is crucial because treatment approaches are completely different. NSCLC is often treated with surgery, radiation, and chemotherapy, while SCLC, due to its aggressive and widespread nature, is primarily managed with chemotherapy, often combined with radiation for limited disease.

What are the main risk factors for developing lung cancer?

The primary risk factor for lung cancer is cigarette smoking, which accounts for over 85% of cases. Other significant risk factors include second-hand smoke exposure, asbestos, radon, and chronic obstructive pulmonary disease (COPD).

How is a solitary pulmonary nodule (SPN) evaluated for malignancy?

SPNs are evaluated based on features like patient age, smoking history, nodule size, border irregularity, and calcification patterns. Low-probability nodules are serially CT-scanned. Intermediate-probability nodules (1 cm or larger) undergo a PET scan. High-probability nodules typically require biopsy (transbronchial, transthoracic) followed by lobectomy if malignancy is confirmed.

What are paraneoplastic syndromes, and which lung cancer type are they often associated with?

Paraneoplastic syndromes are remote effects of cancer, caused by substances secreted by tumor cells. Examples include SIADH and ectopic ACTH secretion (both commonly seen in SCLC), PTH-like hormone secretion (squamous cell carcinoma), and Eaton–Lambert syndrome (SCLC). They can be important indicators of underlying lung cancer.